Navigation Links
Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference
Date:11/22/2011

SAN DIEGO, Nov. 22, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the 23rd Annual Piper Jaffray Healthcare Conference at the Palace Hotel in New York City November 29-30, 2011.

Ronald M. Lindsay, Ph.D., Director and EVP of Research and Development and Paul V. Maier, CFO, will present on Tuesday, November 29, 2011 beginning at 8:30 a.m. ET, to provide an overview of and update on the Company.  The presentation is expected to last approximately 30 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com.  An audio replay will be available for 30 days following the initial presentation web cast.  

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sequenom to Host Analyst Day on Monday, November 14, 2011
2. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
3. Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011
4. Sequenom Center for Molecular Medicine Announces Launch of MaterniT21™ Noninvasive Prenatal Test for Down Syndrome
5. Sequenom Introduces iPLEX® ADME PGx Panel on MassARRAY® System
6. Sequenom, Inc. Announces Date of Second Quarter 2011 Financial Results and Conference Call
7. Sequenom Enters Into New $30.0 Million Credit Facility
8. Sequenom Announces Participation at Jefferies 2011 Global Healthcare Conference
9. Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study
10. Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study
11. Sequenom Announces Exercise in Full of Underwriters Option to Purchase Additional Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee ... honoring scientists who have made outstanding contributions to analytical chemistry and applied ... the world’s leading conference and exposition for laboratory science, which will be held ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):